Example of Current Treatment Options in Allergy format
Recent searches

Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format Example of Current Treatment Options in Allergy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Current Treatment Options in Allergy — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Medicine (miscellaneous) #175 of 238 down down by None rank
Immunology and Allergy #151 of 182 down down by None rank
journal-quality-icon Journal quality:
Medium
calendar-icon Last 4 years overview: 157 Published Papers | 161 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 20/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 8.4
SJR: 2.078
SNIP: 1.475
open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.8
SJR: 0.866
SNIP: 1.035
open access Open Access
recommended Recommended

SAGE

Quality:  
High
CiteRatio: 5.9
SJR: 0.705
SNIP: 1.039
open access Open Access
recommended Recommended

SAGE

Quality:  
High
CiteRatio: 8.8
SJR: 1.436
SNIP: 1.725

Journal Performance & Insights

CiteRatio

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures actual citations received relative to citations expected for the journal's category.

1.0

CiteRatio for Current Treatment Options in Allergy from 2016 - 2020
Year Value
2020 1.0
graph view Graph view
table view Table view

0.194

Year Value
2020 0.194
graph view Graph view
table view Table view

insights Insights

  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • This journal’s SNIP is in the top 10 percentile category.

Current Treatment Options in Allergy

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Current Treatment Options in Allergy

Approved by publishing and review experts on SciSpace, this template is built as per for Current Treatment Options in Allergy formatting guidelines as mentioned in Springer author instructions. The current version was created on and has been used by 995 authors to write and format their manuscripts to this journal.

i
Last updated on
20 Jul 2020
i
ISSN
1606-8610
i
Open Access
Hybrid
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1007/S40521-013-0006-5
Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
Katharina Marth1, Margarete Focke-Tejkl1, Christian Lupinek1, Rudolf Valenta1, Verena Niederberger1

Abstract:

Allergic diseases are among the most common health issues worldwide. Specific immunotherapy has remained the only disease-modifying treatment, but it is not effective in all patients and may cause side effects. Over the last 25 years, allergen molecules from most prevalent allergen sources have been isolated and produced as r... Allergic diseases are among the most common health issues worldwide. Specific immunotherapy has remained the only disease-modifying treatment, but it is not effective in all patients and may cause side effects. Over the last 25 years, allergen molecules from most prevalent allergen sources have been isolated and produced as recombinant proteins. Not only are these molecules useful in improved allergy diagnosis, but they also have the potential to revolutionize the treatment of allergic disease by means of immunotherapy. Panels of unmodified recombinant allergens have already been shown to effectively replace natural allergen extracts in therapy. Through genetic engineering, several molecules have been designed with modified immunological properties. Hypoallergens have been produced that have reduced IgE binding capacity but retained T cell reactivity and T cell peptides which stimulate allergen-specific T cells, and these have already been investigated in clinical trials. New vaccines have been recently created with both reduced IgE and T cell reactivity but retained ability to induce protective allergen-specific IgG antibodies. The latter approach works by fusing per se non-IgE reactive peptides derived from IgE binding sites of the allergens to a virus protein, which acts as a carrier and provides the T-cell help necessary for immune stimulation and protective antibody production. In this review, we will highlight the different novel approaches for immunotherapy and will report on prior and ongoing clinical studies. read more read less

Topics:

Immunoglobulin E (53%)53% related to the paper, Immunotherapy (53%)53% related to the paper, Allergen (51%)51% related to the paper, Allergy (51%)51% related to the paper, T cell (50%)50% related to the paper
View PDF
61 Citations
open accessOpen access Journal Article DOI: 10.1007/S40521-018-0176-2
Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis
Martin Penagos1, Aarif O. Eifan1, Stephen R. Durham1, Guy W. Scadding1

Abstract:

Subcutaneous and sublingual immunotherapy are effective for allergic rhinitis. An important question is whether allergen immunotherapy provides a sustained clinical effect after treatment cessation. In view of potential side effects, cost and the necessary patient commitment, long-term benefit is an important consideration fo... Subcutaneous and sublingual immunotherapy are effective for allergic rhinitis. An important question is whether allergen immunotherapy provides a sustained clinical effect after treatment cessation. In view of potential side effects, cost and the necessary patient commitment, long-term benefit is an important consideration for the recommendation of immunotherapy over standard pharmacotherapy. In this review, we analyse the existing evidence for long-term effects of both routes of administration in the context of double-blind, placebo-controlled, randomised clinical trials that included a follow-up phase of at least 1 year after treatment cessation. Overall, evidence suggests that 3 years of either subcutaneous or sublingual immunotherapy result in clinical benefit and immunological changes consistent with allergen-specific tolerance sustained for at least 2–3 years after treatment cessation. The data presented here support recommendations in international guidelines that both routes of administration should be continued for a minimum of 3 years. Gaps in the evidence remain regarding the long-term efficacy of immunotherapy for perennial rhinitis and studies performed in children. read more read less

Topics:

Allergen immunotherapy (66%)66% related to the paper
View PDF
48 Citations
open accessOpen access Journal Article DOI: 10.1007/S40521-014-0038-5
Is The Allergen Really Needed in Allergy Immunotherapy

Abstract:

Immunotherapy for type I allergies is well established and is regarded to be the most efficient treatment option besides allergen avoidance. As of today, different forms of allergen preparations are used in this regard, as well as different routes of application. Virus-like particles (VLPs) represent a potent vaccine platform... Immunotherapy for type I allergies is well established and is regarded to be the most efficient treatment option besides allergen avoidance. As of today, different forms of allergen preparations are used in this regard, as well as different routes of application. Virus-like particles (VLPs) represent a potent vaccine platform with proven immunogenicity and clinical efficacy. The addition of toll-like receptor ligands and/or depot-forming adjuvants further enhances activation of innate as well as adaptive immune responses. CpG motifs represent intensively investigated and potent direct stimulators of plasmacytoid dendritic cells and B cells, while T cell responses are enhanced indirectly through increased antigen presentation and cytokine release. This article will focus on the function of VLPs loaded with DNA rich in nonmethylated CG motifs (CpGs) and the clinical experience gained in the treatment of allergic rhinitis, demonstrating clinical efficacy also if administered without allergens. Several published studies have demonstrated a beneficial impact on allergic symptoms by treatment with CpG-loaded VLPs. Subcutaneous injection of VLPs loaded with CpGs was tested with or without the adjuvant alum in the presence or absence of an allergen. The results encourage further investigation of VLPs and CpG motifs in immunotherapy, either as a stand-alone product or as adjuvants for allergen-specific immunotherapy. read more read less

Topics:

Adjuvant (54%)54% related to the paper, Immunotherapy (53%)53% related to the paper, Allergy (50%)50% related to the paper
View PDF
40 Citations
open accessOpen access Journal Article DOI: 10.1007/S40521-013-0003-8
Epicutaneous Immunotherapy for Aeroallergen and Food Allergy
Gabriela Senti1, Seraina von Moos1, Thomas M. Kündig1

Abstract:

IgE-mediated allergies today affect up to 30 % of the population in industrialized countries. Allergen immunotherapy is the only disease-modifying treatment option with a long-term effect. However, very few patients (<5 %) choose immunotherapy, due to the long treatment duration (between 3–5 years) and possible local and syst... IgE-mediated allergies today affect up to 30 % of the population in industrialized countries. Allergen immunotherapy is the only disease-modifying treatment option with a long-term effect. However, very few patients (<5 %) choose immunotherapy, due to the long treatment duration (between 3–5 years) and possible local and systemic allergic side effects of the allergen administrations. The latter occur when an allergen accidentally reaches the blood circulation. Therefore, the ideal application route for allergen immunotherapy should be characterized by two hallmarks: firstly, by a high number of potent antigen-presenting cells, which enhance efficacy and thus shorten treatment duration. Secondly, the allergen administration site is ideally non-vascularized, so that inadvertent systemic distribution of the allergen and consequent systemic allergic side effects are minimized. The epidermis contains high numbers of potent antigen-presenting Langerhans cells and, as an epithelium, is non-vascularized. Therefore, the epidermis represents an interesting administration route. Historical evidence for the clinical efficacy of epicutaneous allergy immunotherapy (EPIT) has now been strengthened by a number of recent double-blinded placebo-controlled clinical trials performed by independent groups. We review the immunological rationale, history and clinical experience with epicutaneous allergy immunotherapy. read more read less

Topics:

Allergen immunotherapy (70%)70% related to the paper, Allergy (55%)55% related to the paper, Food allergy (54%)54% related to the paper, Allergen (51%)51% related to the paper, Population (51%)51% related to the paper
View PDF
35 Citations
open accessOpen access Journal Article DOI: 10.1007/S40521-014-0013-1
Allergen-Specific Immunotherapy in Asthma.
Marek Jutel1

Abstract:

Current asthma therapies can effectively control symptoms and the on-going inflammatory process; however, they do not affect the underlying, dysregulated immune response. Thus, they are limited to blunting the progression of the disease, which relapses on ceasing the treatment. Allergen-specific immunotherapy (AIT) is the onl... Current asthma therapies can effectively control symptoms and the on-going inflammatory process; however, they do not affect the underlying, dysregulated immune response. Thus, they are limited to blunting the progression of the disease, which relapses on ceasing the treatment. Allergen-specific immunotherapy (AIT) is the only etiology-based treatment capable of disease modification. Recent evidence provided a plausible explanation for its multiple mechanisms inducing both rapid desensitization and long-term allergen-specific immune tolerance, as well as the suppression of allergic inflammation in the affected tissues. Although the current guideline documents give both subcutaneous (SCIT) and sublingual (SLIT) immunotherapy a conditional recommendation in allergic asthma due to the moderate and low quality of evidence, respectively, a growing body of evidence from double-blind, placebo-controlled studies shows that both SLIT and SCIT are effective in reducing symptom scores and medication use, improving quality of life, and inducing favorable changes in specific immunologic markers. Due to the very limited evidence from head-to-head comparative studies and variability of the end-point used in different studies, it is currently not possible to assess superiority of either route of vaccine administration. read more read less

Topics:

Omalizumab (52%)52% related to the paper, Allergy (52%)52% related to the paper, Immunotherapy (51%)51% related to the paper, Allergic inflammation (51%)51% related to the paper, Asthma (50%)50% related to the paper
View PDF
35 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Current Treatment Options in Allergy.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Current Treatment Options in Allergy in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Current Treatment Options in Allergy guidelines and auto format it.

2. Do you follow the Current Treatment Options in Allergy guidelines?

Yes, the template is compliant with the Current Treatment Options in Allergy guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Current Treatment Options in Allergy?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Current Treatment Options in Allergy citation style.

4. Can I use the Current Treatment Options in Allergy templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Current Treatment Options in Allergy.

5. Can I use a manuscript in Current Treatment Options in Allergy that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Current Treatment Options in Allergy that you can download at the end.

6. How long does it usually take you to format my papers in Current Treatment Options in Allergy?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Current Treatment Options in Allergy.

7. Where can I find the template for the Current Treatment Options in Allergy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Current Treatment Options in Allergy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Current Treatment Options in Allergy's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Current Treatment Options in Allergy an online tool or is there a desktop version?

SciSpace's Current Treatment Options in Allergy is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Current Treatment Options in Allergy?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Current Treatment Options in Allergy?”

11. What is the output that I would get after using Current Treatment Options in Allergy?

After writing your paper autoformatting in Current Treatment Options in Allergy, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Current Treatment Options in Allergy's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Current Treatment Options in Allergy?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Current Treatment Options in Allergy. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Current Treatment Options in Allergy?

The 5 most common citation types in order of usage for Current Treatment Options in Allergy are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Current Treatment Options in Allergy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Current Treatment Options in Allergy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Current Treatment Options in Allergy in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Current Treatment Options in Allergy Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Current Treatment Options in Allergy formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template